91例初治未联合VEN患者经1个疗程诱导治疗后评估,CR 50例(54.9%),CRi 6例(6.6%),PR 13例(14.3%),NR 22例(24.2%),ORR为75.8%(69/91)。初治IDH1/2突变阳性AML患者中联合VEN组的ORR显著高于未联合组(100%对75.8%,P=0.039)。91例患者中22例为复发/难治患者,其中16例接受未联合VEN的再诱导化疗,治疗后评估CR 6例(37.5%),NR 10例(62.5%)。复发/难治IDH1/2突变阳性AML患者中联合VEN组的CR率高于未联合组(64.3%对37.5%),差异无统计学意义(P=0.272)。. This evidence concerns the gene IDH1 and acute myeloid leukemia.